Lokon Pharma AB   Report issue

For profit Phase 2
Founded: Uppsala Sweden (2011)

Organization Overview

First Clinical Trial
2016
NCT02705196
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Lokon Pharma AB

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Melanoma (Phase 2)

Pancreatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 5